top of page
Search
Biologics R&D: select news
Reversible host cell surface remodelling limits immune recognition and maximizes survival of Plasmodium falciparum gametocytes
https://pubmed.ncbi.nlm.nih.gov/40354414/
jeanfrancoismaison
May 131 min read
Ā
Ā
Ā
Need for inclusion of high-risk populations and standardisation of immunogenicity outcomes in adult pneumococcal vaccine trials
https://pubmed.ncbi.nlm.nih.gov/40354795/
jeanfrancoismaison
May 131 min read
Ā
Ā
Ā
Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: a prospective pan-tumor cohort study
https://pubmed.ncbi.nlm.nih.gov/40355283/
jeanfrancoismaison
May 131 min read
Ā
Ā
Ā
Current status of next-generation vaccines against mpox virus: a scoping review
https://pubmed.ncbi.nlm.nih.gov/40356988/
jeanfrancoismaison
May 131 min read
Ā
Ā
Ā
Ezh2 Shapes T Cell Plasticity to Drive Atherosclerosis
https://pubmed.ncbi.nlm.nih.gov/39917842/
jeanfrancoismaison
May 131 min read
Ā
Ā
Ā
Unravelling key signaling pathways for the therapeutic targeting of non-small cell lung cancer
https://pubmed.ncbi.nlm.nih.gov/40090536/
jeanfrancoismaison
May 131 min read
Ā
Ā
Ā
Safety and immunogenicity of a bivalent Ebola virus and Sudan virus ChAdOx1 vectored vaccine in adults in the UK: an open-label, non-randomised, first-in-human, phase 1 clinical trial
https://pubmed.ncbi.nlm.nih.gov/39922207/
jeanfrancoismaison
May 121 min read
Ā
Ā
Ā
A gamma-irradiated pneumococcal vaccine elicits superior immunogenicity in comparison to heat or chemically inactivated whole-cell vaccines
https://pubmed.ncbi.nlm.nih.gov/40048932/
jeanfrancoismaison
May 121 min read
Ā
Ā
Ā
A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (FluzoneĀ® or FlublokĀ®) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in
https://pubmed.ncbi.nlm.nih.gov/40107003/
jeanfrancoismaison
May 121 min read
Ā
Ā
Ā
Immunogenicity and safety of monovalent and bivalent SARS-CoV-2 variant adapted RBD-based protein booster vaccines in adults previously immunized with different vaccine platforms: A phase II/III, rand
https://pubmed.ncbi.nlm.nih.gov/40179522/
jeanfrancoismaison
May 121 min read
Ā
Ā
Ā
Comparison of vaccine-induced immune thrombocytopenia and thrombosis cases following two adenovirus-vectored COVID-19 vaccines
https://pubmed.ncbi.nlm.nih.gov/40348868/
jeanfrancoismaison
May 121 min read
Ā
Ā
Ā
BactiVac, the Bacterial Vaccines Network
https://pubmed.ncbi.nlm.nih.gov/40349456/
jeanfrancoismaison
May 121 min read
Ā
Ā
Ā
Design and construction of a fast synthetic modified vaccinia virus Ankara reverse genetics system for advancing vaccine development
https://pubmed.ncbi.nlm.nih.gov/40351316/
jeanfrancoismaison
May 121 min read
Ā
Ā
Ā
Prevention and interception trials in inflammatory bowel disease: an international taskforce assessment on clinical trial design
https://pubmed.ncbi.nlm.nih.gov/40187359/
jeanfrancoismaison
May 121 min read
Ā
Ā
Ā
RNAi-mediated silencing of SOD1 profoundly extends survival and functional outcomes in ALS mice
https://pubmed.ncbi.nlm.nih.gov/40349108/
jeanfrancoismaison
May 121 min read
Ā
Ā
Ā
Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial
https://pubmed.ncbi.nlm.nih.gov/40350430/
jeanfrancoismaison
May 121 min read
Ā
Ā
Ā
Advancing ORFV-Based Therapeutics to the Clinical Stage
https://pubmed.ncbi.nlm.nih.gov/40346732/
jeanfrancoismaison
May 111 min read
Ā
Ā
Ā
From receptor to response: dissecting the TLR4 pathway in diabetic neuropathy
https://pubmed.ncbi.nlm.nih.gov/40347407/
jeanfrancoismaison
May 111 min read
Ā
Ā
Ā
Advancing ORFV-Based Therapeutics to the Clinical Stage
https://pubmed.ncbi.nlm.nih.gov/40346732/
jeanfrancoismaison
May 111 min read
Ā
Ā
Ā
Effectiveness and Safety of Respiratory Syncytial Virus Vaccine for US Adults Aged 60 Years or Older
https://pubmed.ncbi.nlm.nih.gov/40343698/
jeanfrancoismaison
May 111 min read
Ā
Ā
Ā
bottom of page